Parkinson Disease Dementia
📧 Sign up to get email alerts when something new happens for Parkinson Disease Dementia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: Environmental and Reproductive Health Risk for Lewy Body Dementia
A clinical trial update from the University of California, San Diego assessing environmental and reproductive health risk in Lewy body demen…
-
FDA approval · 2024-05-08FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for rivastigmine filed by Sandoz Inc, resulting in an approved modification to the existing rivastig…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Ambroxol as a Treatment for Parkinson's Disease Dementia [Phase 2]
Phase 2 clinical trial exploring ambroxol as a treatment for Parkinson's disease dementia is ongoing or status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease [Phase 4]
Phase 4 trial update on cholinergic neurotransmission related to mobility and cognition in Parkinson disease and Parkinson disease dementia.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia [NA]
A completed clinical trial studying peer mentor support and caregiver education for Lewy body-related dementias; results posted in 2023.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-26Clinical Trial Update: A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology [Phase 2]
Phase 2 clinical trial update for E2027 in participants with dementia with Lewy bodies or Parkinson's disease dementia; study completed with…
-
CLINICAL_TRIALS trial_result · 2020-05-20Clinical Trial Update: Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD) [Phase 2]
Phase 2 clinical trial evaluating nelotanserin for REM Sleep Behavior Disorder in patients with dementia-related conditions has completed wi…
-
FDA approval · 2019-11-26FDA Approved: RIVASTIGMINE TRANSDERMAL SYSTEM — Original Application (Breckenridge Pharmaceutical, Inc.)
FDA approved Breckenridge Pharmaceutical's rivastigmine transdermal system (patch) through an Original ANDA, expanding generic options for t…
-
FDA approval · 2019-07-23FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Nivagen Pharmaceuticals, Inc.)
FDA approved a supplemental application for rivastigmine tartrate from Nivagen Pharmaceuticals, Inc., enabling a generic rivastigmine tartra…
-
FDA approval · 2019-07-22FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for rivastigmine tartrate by Alembic Pharmaceuticals Limited, authorizing a generic rivastigmine tar…
-
FDA approval · 2019-07-16FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for a generic rivastigmine tartrate product from Dr. Reddy's Laboratories (ANDA). Rivastigmine tartr…
-
CLINICAL_TRIALS trial_result · 2019-04-19Clinical Trial Update: SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) [Phase 2]
Phase 2 trial of SYN120 in Parkinson's Disease Dementia has completed; results posted in 2019.
-
FDA approval · 2019-04-16FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for rivastigmine tartrate filed by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2019-04-16FDA Approved: RIVASTIGMINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for rivastigmine from Mylan Pharmaceuticals Inc. under ANDA 205622, updating the generic product's a…
-
FDA approval · 2019-04-04FDA Approved: RIVASTIGMINE TARTRATE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application from Aurobindo Pharma Limited for rivastigmine tartrate (generic), authorizing its use for treat…
-
FDA approval · 2019-03-21FDA Approved: RIVASTIGMINE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for rivastigmine by Amneal Pharmaceuticals LLC under ANDA207308.
-
FDA approval · 2019-03-04FDA Approved: RIVASTIGMINE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves the original generic application for rivastigmine from Zydus Pharmaceuticals USA Inc., enabling the marketing of rivastigmine p…
-
FDA approval · 2019-01-08FDA Approved: RIVASTIGMINE — Original Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals' generic rivastigmine via Original Application (ANDA). The product is indicated for the treatment of…
-
FDA approval · 2018-12-18FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for rivastigmine submitted by Sandoz Inc. This action updates rivastigmine's regulatory status t…
-
FDA approval · 2018-06-20FDA Approved: RIVASTIGMINE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved an original generic rivastigmine application from Mylan for treatment of dementia associated with Alzheimer's disease and Parki…
-
FDA approval · 2017-09-28FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Chartwell RX, LLC)
FDA approves the original application for rivastigmine tartrate (generic) manufactured by Chartwell RX, LLC.
-
FDA approval · 2017-02-13FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Nivagen Pharmaceuticals, Inc.)
The FDA approved the original application for rivastigmine tartrate from Nivagen Pharmaceuticals, Inc., establishing a generic version of ri…
-
FDA approval · 2016-11-02FDA Approved: RIVASTIGMINE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for rivastigmine by Sandoz Inc, updating the approval status of this product.
-
CLINICAL_TRIALS trial_result · 2016-10-31Clinical Trial Update: Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's. [Phase 1, Phase 2]
Completion of a Phase 1/2 trial evaluating nucleus basalis deep brain stimulation for thinking and memory problems in Parkinson's disease de…
-
FDA approval · 2016-03-25FDA Approved: RIVASTIGMINE TARTRATE — Original Application (Aurobindo Pharma Limited)
FDA approved an original generic application for rivastigmine tartrate from Aurobindo Pharma Limited, enabling a generic version of rivastig…